JAK inhibitors, a new class of tsDMARDs, have shown superior efficacy in RCTs for RA compared to other biologics. Real-world studies highlight JAK inhibitors' benefits in clinical disease activity, ...

Eighty-four patients received ≥ 1 dose of pelabresib and ruxolitinib. The median age was 68 (range, 37-85) years; 24% of patients were intermediate-1 risk, 61% were intermediate-2 risk, and 16% were ...

The JAK2 gene is a protein-coding gene of the Janus kinase family. It plays a role in cellular signaling. Evidence notes connections between this gene and some medical conditions. Variations in this ...

Please provide your email address to receive an email when new articles are posted on . The FDA has called for additional warning labels on janus kinase inhibitors after a safety review found this ...

Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell ...

Ruxolitinib cream is the first FDA-approved JAK inhibitor for skin repigmentation in people with vitiligo, paving the way for additional oral and topical JAK inhibitors to treat this autoimmune ...

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, ...